Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.20%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-05-13 | -0.04 | -0.06 | -36.4% |
| 2026-03-25 | -0.06 | -0.04 | +36.8% |
| 2025-11-13 | -0.22 | -0.06 | +72.7% |
| 2025-08-14 | -0.18 | -0.16 | +13.5% |
| 2025-05-14 | -0.33 | -0.24 | +28.4% |
| 2025-03-27 | -0.31 | -0.16 | +48.4% |
| 2024-11-13 | 0.14 | Pending | -- |
| 2024-08-08 | -0.13 | 0.01 | +107.9% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$5.3M | -$5.6M | — | -$5.6M | -0.06 |
| 2025-12-31 | — | -$3.8M | -$3.9M | — | -$4.0M | -0.04 |
| 2025-09-30 | — | -$4.2M | -$4.5M | — | -$4.6M | -0.06 |
| 2025-06-30 | — | -$5.7M | -$6.2M | — | -$6.2M | -0.16 |
| 2025-03-31 | — | -$8.7M | -$8.8M | — | -$8.9M | -0.24 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-03-13 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 120,312 | $300.8K |
| 2026-03-13 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 120,312 | $94.4K |
| 2026-03-09 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 181,219 | $362.4K |
| 2026-03-09 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 152,361 | $119.6K |
| 2026-02-19 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 185,937 | $328.1K |
| 2026-02-19 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 185,937 | $328.1K |
| 2026-02-19 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 185,937 | $141.8K |
| 2026-02-19 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 185,937 | $141.8K |
| 2026-01-08 | TOM PENNY | Officer | 6,533 | $8.4K |
| 2025-12-23 | ZEDELMAYER CHRISTINE | Chief Operating Officer | 100,000 | $150.0K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Janus Henderson Group PLC | 6.5M | $14.7M | 0.1% |
| Adage Capital Partners GP L.L.C. | 5.3M | $12.0M | 0.1% |
| Decheng Capital LLC | 4.4M | $10.1M | 0.1% |
| Adar1 Capital Management, LLC | 3.7M | $8.4M | 0.1% |
| Woodline Partners LP | 3.5M | $7.9M | 0.1% |
| Aberdeen Group plc | 3.4M | $7.6M | 0.1% |
| RA Capital Management, L.P. | 3.1M | $7.0M | 0.0% |
| Vanguard Capital Management LLC | 1.8M | $4.0M | 0.0% |
| Balyasny Asset Management LP | 1.6M | $3.7M | 0.0% |
| Eversept Partners, LP | 1.5M | $3.4M | 0.0% |
$82.3M
2.40
8
$692.0K
1.25
7.21
0.1%
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-05-13 | $-0.04 | $-0.06 | -36.4% |
| 2026-03-25 | $-0.06 | $-0.04 | +36.8% |
| 2025-11-13 | $-0.22 | $-0.06 | +72.7% |
| 2025-08-14 | $-0.18 | $-0.16 | +13.5% |
| 2025-05-14 | $-0.33 | $-0.24 | +28.4% |
| 2025-03-27 | $-0.31 | $-0.16 | +48.4% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($6.38, 8 analysts) | |||
| 10 | $21.75 | +$42.00 (193%) | 13.1R |
| 50 | $108.75 | +$210.00 (193%) | 13.1R |
| 100 | $217.50 | +$420.00 (193%) | 13.1R |
- Elevated short interest (7.21 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| IMXI | 0.239 |
| FLY | 0.219 |
| MPLT | 0.213 |
| ERES.QA | 0.198 |
| LBRX | 0.192 |
| Ticker | Correlation |
|---|---|
| AYRWF | -0.267 |
| BKIKWT.KW | -0.188 |
| NSP | -0.145 |
| PAYC | -0.128 |
| NIQ | -0.119 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.